International Stem Cell (ISCO) Receivables (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Receivables of $723000.0 for Q4 2025, down 31.66% year-over-year from $1.1 million in Q4 2024, and down 28.77% quarter-over-quarter from $1.0 million in Q3 2025.
International Stem Cell (ISCO) Receivables (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Receivables for 16 consecutive years, with $723000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables fell 31.66% year-over-year to $723000.0; the TTM figure through Dec 2025 stood at $723000.0 (down 31.66% YoY), while the FY2025 annual figure was $723000.0, down 31.66% from the prior year.
- Receivables retreated to $723000.0 in Q4 2025 per ISCO's latest filing, from $1.0 million in the prior quarter.
- Across five years, Receivables topped out at $1.1 million in Q2 2025 and bottomed at $427000.0 in Q3 2022.
- Historically, Receivables has averaged $733650.0 across 5 years, with a median of $684000.0 in 2023.
- On a YoY basis, Receivables climbed as much as 109.43% in 2021 and fell as far as 61.6% in 2021.
- International Stem Cell's Receivables stood at $844000.0 in 2021, then dropped by 11.49% to $747000.0 in 2022, then declined by 23.16% to $574000.0 in 2023, then jumped by 84.32% to $1.1 million in 2024, then sank by 31.66% to $723000.0 in 2025.
- Business Quant data shows ISCO's Receivables at $723000.0 in Q4 2025, $1.0 million in Q3 2025, and $1.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 959,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 959,000.00 |
| Dec 31, 2025 | 723,000.00 |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 851,000.00 |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 680,000.00 |
| Jun 30, 2024 | 810,000.00 |
| Mar 31, 2024 | 632,000.00 |
| Dec 31, 2023 | 574,000.00 |
| Sep 30, 2023 | 644,000.00 |
| Jun 30, 2023 | 662,000.00 |
| Mar 31, 2023 | 688,000.00 |
| Dec 31, 2022 | 747,000.00 |
| Sep 30, 2022 | 427,000.00 |
| Jun 30, 2022 | 663,000.00 |
| Mar 31, 2022 | 902,000.00 |
| Dec 31, 2021 | 844,000.00 |
| Sep 30, 2021 | 668,000.00 |
| Jun 30, 2021 | 547,000.00 |